Showing results (41-50 of 79) with videos related to
Sort By:
Pageof 8
Ophthalmic Surgery, Lasers & Imaging Retina|April 30, 2020
Social Cost of Blindness Due to AMD and Diabetic Retinopathy in the United States in 2020Andrew A Moshfeghi, Tereza Lanitis, Georg Kropat, et al.Plos One|June 23, 2012
Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysisYukari C Manabe, Sabine M Hermans, Mohammed Lamorde, et al.American Health & Drug Benefits|August 16, 2014
Estimates of commercial population at high risk for cardiovascular events: impact of aggressive cholesterol reductionKathryn Fitch, Sara W Goldberg, Kosuke Iwasaki, et al.Mayo Clinic Proceedings|December 4, 2009
Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed populationRoss J Simpson, James Signorovitch, Howard Birnbaum, et al.Advances in Therapy|April 21, 2019
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic DrugsNoemi Muszbek, Clare Proudfoot, Marie Fournier, et al.Patient Preference and Adherence|March 11, 2017
Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatmentsLina Eliasson, Anthony P Bewley, Farhan Mughal, et al.Journal of Managed Care & Specialty Pharmacy|October 31, 2019
Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor InhibitorsNoemi Muszbek, Clare Proudfoot, Marie Fournier, et al.Clinicoeconomics and Outcomes Research : CEOR|December 12, 2018
Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapiesCheryl P Ferrufino, Julie Munakata, Wenhui Wei, et al.Contemporary Clinical Trials Communications|December 5, 2024
Modeling severe uncontrolled asthma: Transitioning away from health statesTereza Lanitis, Asif H Khan, Irina Proskorovsky, et al.BMC Public Health|September 5, 2012
Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in UgandaJoseph Sempa, Mark Ssennono, Andreas Kuznik, et al.Pageof 8